Dilworth Paxson LLP is pleased to announce that Dr. Shawn Shiqing Li has joined the firm as a partner and newest member of its intellectual property practice. He will work out of the firm’s Philadelphia office.
Shawn combines his scientific and legal training in assisting clients in the biotechnology, pharmaceutical and other high-tech industries. His practice focuses on counseling clients on comprehensive IP protection strategy; drafting and prosecuting U.S. and international patent applications; rendering patent validity, infringement, freedom to operate, and patentability opinions, including Paragraph IV opinions and certifications; prosecuting patent reexamination; negotiating and preparing complex biotechnology and pharmaceutical licenses and related agreements; and performing IP due diligence in connection with mergers and acquisitions.
Shawn is a native of Shanghai, China and speaks fluent Mandarin. With his unique cross-cultural background, Shawn has assisted major U.S. clients in intellectual property protection matters in China, including strategic counseling, patent, trademark, trade secret enforcement actions in China, and cross-border technology transfers, and joint ventures.
Shawn is also experienced in patent litigation matters involving a large variety of technologies, including pharmaceuticals, formulations, medical devices, and computer software.
In 2003, Shawn received his doctoral degree at New York University School of Medicine, and law degree from the Temple University Beasley School of Law in 2008. Prior to practicing law, Shawn spent three years as a research scientist at the University of Pennsylvania. His research focused on biological and therapeutic systems related to cancer and diabetes.
“We are delighted to add a lawyer of Shawn Li’s quality and skill,” commented “Joseph H. Jacovini, Chairman of the firm. “He is an experienced patent attorney with a Ph.D. in pharmacology, whose strong technical abilities will bring valuable depth to our IP practice. We view his strong relationships in Asia as an exciting opportunity to expand our international client base.”
